Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.

Ronan J. Kelly,Jaffer A. Ajani,Jarosław Kużdżał,Thomas Zander,Eric Van Cutsem,Guillaume Piessen,Guillermo Mendez,Josephine Feliciano,Satoru Motoyama,Astrid Lièvre,Hope E. Uronis,Elena Elimova,Cecile Grootscholten,Karen Geboes,Jenny Zhang,Samira Soleymani,Ming Lei,Prianka Singh,James M. Cleary,Markus Moehler

Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.

2021

4003Background: In CheckMate 577 (NCT02743494), NIVO demonstrated a significant and clinically meaningful improvement in disease-free survival (DFS; primary endpoint) vs placebo (PBO) and was well ...

Keywords:

Medicine
Nivolumab
Internal medicine
Gastroesophageal Junction
Oncology
Placebo
neoadjuvant chemoradiotherapy
Clinical endpoint
Adjuvant
Cancer
Checkmate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations